## Section 1: Identification

### Material
- **Bupropion Hydrochloride Extended-Release Tablets USP (XL) 150 mg and 300 mg**

### Manufacturer
- **Lupin Limited**
  - Goa – 403 722
  - India

### Distributor
- **Lupin Pharmaceuticals, Inc.**
  - 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202
  - United States
  - Tel. 001-410-576-2000
  - Fax. 001-410-576-2221

## Section 2: Hazard(s) Identification

### Section 2, Hazard(s) identification

#### Fire and Explosion
- Expected to be non-combustible.

#### Health
- Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.
- Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL).
- Bupropion hydrochloride extended-release tablets (XL) is contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.
- The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated.
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported.

Environment
No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion Hydrochloride USP</td>
<td>31677-93-7</td>
</tr>
</tbody>
</table>

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGE

Human Overdose Experience
Overdoses of up to 30 grams or more of bupropion have been reported. Seizure was reported in approximately one third of all cases. Other serious reactions reported with overdoses of bupropion alone included hallucinations, loss of consciousness, sinus tachycardia, and ECG changes such as conduction disturbances or arrhythmias. Fever, muscle rigidity, rhabdomyolysis, hypotension, stupor, coma, and respiratory failure have been reported mainly when bupropion was part of multiple drug overdoses.
Although most patients recovered without sequelae, deaths associated with overdoses of bupropion alone have been reported in patients ingesting large doses of the drug. Multiple uncontrolled seizures, bradycardia, cardiac failure, and cardiac arrest prior to death were reported in these patients.

**Overdosage Management**
Consult a Certified Poison Control Center for up-to-date guidance and advice. Telephone numbers for certified poison control centers are listed in the Physicians’ Desk Reference (PDR). Call 1-800-222-1222 or refer to www.poison.org.

There are no known antidotes for bupropion. In case of an overdose, provide supportive care, including close medical supervision and monitoring. Consider the possibility of multiple drug overdose.

## Section 5: Fire-Fighting Measures

### Section 5, Fire-fighting measures

**Fire and Explosion Hazards**  
Assume that this product is capable of sustaining combustion.

**Extinguishing Media**  
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

**Special Firefighting Procedures**  
For single units (packages): No special requirements needed.  
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

**Hazardous Combustion Products**  
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

## Section 6: Accidental Release Measures

### Section 6, Accidental release measures

**Personal Precautions**  
Wear protective clothing and equipment consistent with the degree of hazard.

**Environmental Precautions**  
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

**Clean-up Methods**  
Collect and place it in a suitable, properly labeled container for recovery or disposal.
Section 7: Handling and Storage

Section 7, Handling and storage

Handling
No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

Storage
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Section 8: Exposure Controls/ Personal Protection

Section 8, Exposure controls/personal protection
Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form
Bupropion Hydrochloride Extended-release Tablets USP (XL), 150 mg of bupropion hydrochloride, are off-white to pale yellow, round, biconvex, coated tablets imprinted with “L015” in black ink on one side and plain on the other side.

They are supplied as follows:

NDC 68180-319-06  Bottles of 30’s
NDC 68180-319-09  Bottles of 90’s
NDC 68180-319-02  Bottles of 500’s

Bupropion Hydrochloride Extended-release Tablets USP (XL), 300 mg of bupropion hydrochloride, are off-white to pale yellow, round, biconvex, coated tablets imprinted with “L016” in black ink on one side and plain on the other side.

They are supplied as follows:

NDC 68180-320-06  Bottles of 30’s
NDC 68180-320-09  Bottles of 90’s
NDC 68180-320-02  Bottles of 500’s

Section 10: Stability and Reactivity

Section 10, Stability and reactivity
Stable under recommended storage conditions.
Section 11: Toxicological Information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Lifetime carcinogenicity studies were performed in rats and mice at doses up to 300 and 150 mg/kg/day bupropion hydrochloride, respectively. These doses are approximately 7 and 2 times the maximum recommended human dose (MRHD), respectively, on a mg/m² basis.

In the rat study there was an increase in nodular proliferative lesions of the liver at doses of 100 to 300 mg/kg/day of bupropion hydrochloride (approximately 2 to 7 times the MRHD on a mg/m² basis); lower doses were not tested. The question of whether or not such lesions may be precursors of neoplasms of the liver is currently unresolved. Similar liver lesions were not seen in the mouse study, and no increase in malignant tumors of the liver and other organs was seen in either study.

Bupropion produced a positive response (2 to 3 times control mutation rate) in 2 of 5 strains in one Ames bacterial mutagenicity assay, but was negative in another. Bupropion produced an increase in chromosomal aberrations in 1 of 3 in vivo rat bone marrow cytogenetic studies.

A fertility study in rats at doses up to 300 mg/kg/day revealed no evidence of impaired Fertility.

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

IATA/ICAO - Not Regulated

| IATA Proper shipping Name | : N/A |
| IATA UN/ID No             | : N/A |
| IATA Hazard Class         | : N/A |
| IATA Packaging Group      | : N/A |
| IATA Label                | : N/A |
**IMDG - Not Regulated**
- IMDG Proper shipping Name: N/A
- IMDG UN/ID No: N/A
- IMDG Hazard Class: N/A
- IMDG Flash Point: N/A
- IMDG Label: N/A

**DOT - Not Regulated**
- DOT Proper shipping Name: N/A
- DOT UN/ID No: N/A
- DOT Hazard Class: N/A
- DOT Flash Point: N/A
- DOT Packing Group: N/A
- DOT Label: N/A

---

### Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

### Section 16: Other Information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.